Teva Pharmaceutical Industries ADR (TEVA) Stock Price, Quote & News

Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 972 3 914 8213

Website: www.tevapharm.com

Address:

124 Dvora HaNevi’a St., Tel Aviv-Yafo, Israel

BluntForceOptions Jan. 16 at 6:08 PM

$TEVA The "crack" in the tape is widening. Risk/reward has officially flipped to the downside. 📉 IMO, the cycle has shifted from vertical extension to distribution... the easy upside is in the rearview. Playing the unwind via Jan 2027 Puts... defined risk with the duration needed to let the mean reversion play out.

1 · Reply

ZacksResearch Jan. 16 at 1:53 PM

$ANIP vs. $TEVA — Which pharma stock should you buy? 💊 ANI Pharmaceuticals is riding high on Cortrophin Gel’s progress, projecting a 55-65% sales increase in 2026, paired with a Zacks Rank #2 (Buy). In contrast, TEVA maintains its biosimilars strategy, with a Zacks Rank #3 (Hold). See what makes ANIP stand out as an investment pick 👉 https://www.zacks.com/stock/news/2818642/anip-vs-teva-which-drug-stock-is-the-better-buy-right-now?cid=sm-stocktwits-2-2818642-body-29206&ADID=SYND_STOCKTWITS_TWEET_2_2818642_BODY_29206

0 · Reply

ZacksResearch Jan. 16 at 12:53 PM

$ANIP vs. $TEVA — which drug stock actually deserves your capital right now? 💊⚖️ This head-to-head breaks down the investment case between ANI Pharmaceuticals and Teva, framing which name stands out as the better buy in the current setup. See how the comparison stacks up and which stock comes out ahead 👉 https://www.zacks.com/stock/news/2818642/anip-vs-teva-which-drug-stock-is-the-better-buy-right-now?cid=sm-stocktwits-2-2818642-teaser-29205&ADID=SYND_STOCKTWITS_TWEET_2_2818642_TEASER_29205

0 · Reply

Warbucks007 Jan. 16 at 4:42 AM

$TEVA Still holding from sub $8. Keep on pushing

0 · Reply

DocDriz Jan. 15 at 7:03 PM

$TEVA Just sold my very last Jan 2026 $20 calls 😭. Bought $1.505 sold $12.705. I never wanted to let you go.

1 · Reply

Phoenixrise1 Jan. 15 at 5:04 PM

$TEVA

0 · Reply

Hopewisper Jan. 15 at 3:19 PM

$TEVA Stop the terror😎

0 · Reply

tkstockpicker Jan. 15 at 2:45 PM

$TEVA added

0 · Reply

LakersandVRX Jan. 14 at 10:33 PM

$TEVA Chaos in the market. Stability in TEVA.

1 · Reply

TheMonz Jan. 14 at 10:19 PM

$TEVA https://www.tevapharm.com/news-and-media/latest-news/ajovy-fremanezumab-vfrm-significantly-reduced-monthly-migraine-and-headache-days-in-children-and-adole/

0 · Reply

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

Jan 14, 2026, 8:01 AM EST - 2 days ago

Teva Is No Longer A Turnaround Story, It's A Growth One

Jan 13, 2026, 2:46 PM EST - 3 days ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 12:26 PM EST - 4 days ago

Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug

RPRX

Jan 12, 2026, 10:46 AM EST - 4 days ago

Why Investors Are So Optimistic on Teva

Jan 11, 2026, 6:00 PM EST - 5 days ago

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Jan 11, 2026, 5:00 PM EST - 5 days ago

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Jan 5, 2026, 4:30 PM EST - 11 days ago

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 2, 2026, 8:58 AM EST - 14 days ago

Top 2 Health Care Stocks That May Crash In Q1

EXAS

Dec 24, 2025, 8:36 AM EST - 23 days ago

S&P Global Ratings Upgrades Teva to ‘BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

Dec 23, 2025, 6:08 PM EST - 23 days ago

Teva Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)

Dec 19, 2025, 3:40 AM EST - 4 weeks ago

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

Dec 9, 2025, 8:00 AM EST - 5 weeks ago

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Dec 4, 2025, 2:08 PM EST - 6 weeks ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 25, 2025, 8:10 AM EST - 7 weeks ago

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Nov 21, 2025, 4:30 PM EST - 2 months ago

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December

Nov 19, 2025, 8:07 AM EST - 2 months ago

Teva seeks startups to help solve global pharmaceutical challenges

Nov 18, 2025, 8:58 AM EST - 2 months ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 14, 2025, 10:38 AM EST - 2 months ago

Generics Stalwart Teva Has Turned A Corner In Its Specialty Medicines Business

Nov 10, 2025, 2:51 PM EST - 2 months ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 7, 2025, 6:00 PM EST - 2 months ago

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

Nov 5, 2025, 1:02 PM EST - 2 months ago

Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working

Nov 5, 2025, 1:01 PM EST - 2 months ago

Teva Pharmaceutical Industries Limited (TEVA) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 11:30 AM EST - 2 months ago

Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook

Nov 5, 2025, 9:14 AM EST - 2 months ago

Teva Pharmaceuticals stock surges 12% as branded drug sales outperform

Nov 5, 2025, 7:44 AM EST - 2 months ago

Teva Pharm third-quarter profit tops estimates as branded drugs gain

Nov 5, 2025, 7:00 AM EST - 2 months ago

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS

Oct 31, 2025, 4:30 PM EDT - 2 months ago

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November

Oct 30, 2025, 11:45 AM EDT - 2 months ago

Blood pressure medicine recalled over high levels of cancer-causing chemical

Oct 20, 2025, 4:30 PM EDT - 3 months ago

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

Oct 17, 2025, 12:18 PM EDT - 3 months ago

Teva Vs. Viatris: Who Will Dominate In President Trump's America?

VTRS

Oct 10, 2025, 3:00 PM EDT - 3 months ago

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

Oct 7, 2025, 4:07 AM EDT - 3 months ago

Teva Pharmaceutical: Turnaround Driven By Huge Pipeline Upside

Sep 25, 2025, 4:30 PM EDT - 4 months ago

Teva Releases Q3 2025 Aide Memoire

Sep 25, 2025, 4:30 PM EDT - 4 months ago

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

Sep 25, 2025, 11:42 AM EDT - 4 months ago

Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors

Sep 24, 2025, 7:23 AM EDT - 4 months ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 22, 2025, 2:53 PM EDT - 4 months ago

Teva Pharmaceutical Industries Limited - Special Call

Sep 20, 2025, 10:15 PM EDT - 4 months ago

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Sep 17, 2025, 8:00 AM EDT - 4 months ago

Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation

Sep 16, 2025, 4:30 PM EDT - 4 months ago

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

Sep 9, 2025, 12:57 PM EDT - 4 months ago

Teva Pharmaceutical Industries Limited (TEVA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 5, 2025, 3:57 PM EDT - 4 months ago

Colorado must face Teva's lawsuit over free allergy pen law

Sep 2, 2025, 4:30 PM EDT - 4 months ago

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

Aug 28, 2025, 9:17 AM EDT - 5 months ago

US FDA approves Teva Pharmaceuticals' generic obesity drug

Aug 28, 2025, 1:43 AM EDT - 5 months ago

Teva's Pivot To (Innovative) Growth: Re-Rating Should Continue

Aug 19, 2025, 9:00 AM EDT - 5 months ago

Teva Debuts Autumn Winter 2025 Collection Inspired By “For Playground Earth”

Aug 5, 2025, 6:16 PM EDT - 5 months ago

US FDA approves Teva's Ajovy for migraine prevention in children

Jul 31, 2025, 3:27 PM EDT - 6 months ago

Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside

Jul 30, 2025, 12:40 PM EDT - 6 months ago

Teva CEO: Our supply chain puts us in a strong position

BluntForceOptions Jan. 16 at 6:08 PM

1 · Reply

ZacksResearch Jan. 16 at 1:53 PM

0 · Reply

ZacksResearch Jan. 16 at 12:53 PM

0 · Reply

Warbucks007 Jan. 16 at 4:42 AM

$TEVA Still holding from sub $8. Keep on pushing

0 · Reply

DocDriz Jan. 15 at 7:03 PM

$TEVA Just sold my very last Jan 2026 $20 calls 😭. Bought $1.505 sold $12.705. I never wanted to let you go.

1 · Reply

Phoenixrise1 Jan. 15 at 5:04 PM

$TEVA

0 · Reply

Hopewisper Jan. 15 at 3:19 PM

$TEVA Stop the terror😎

0 · Reply

tkstockpicker Jan. 15 at 2:45 PM

$TEVA added

0 · Reply

LakersandVRX Jan. 14 at 10:33 PM

$TEVA Chaos in the market. Stability in TEVA.

1 · Reply

TheMonz Jan. 14 at 10:19 PM

$TEVA https://www.tevapharm.com/news-and-media/latest-news/ajovy-fremanezumab-vfrm-significantly-reduced-monthly-migraine-and-headache-days-in-children-and-adole/

0 · Reply

Pao_Light Jan. 14 at 8:46 PM

$TEVA how far do you think this may get? I have been holding it since 18$ and it seems stretched now. Can anybody give an estimate based on TA or valuation?

3 · Reply

Phoenixrise1 Jan. 14 at 7:56 PM

$TEVA $33 is her for the taking

0 · Reply

layahoo Jan. 14 at 4:07 PM

$TEVA Outperforming the market per usual.

1 · Reply

tkstockpicker Jan. 14 at 3:35 PM

$TEVA Back in for a trade

0 · Reply

Jessypenny Jan. 14 at 11:02 AM

$DRTS When you are on a list with these companies $MRK $PFE $TEVA its a great sign 💪

3 · Reply

Phoenixrise1 Jan. 13 at 8:56 PM

$TEVA strong support here

0 · Reply

OX50 Jan. 13 at 6:21 PM

$TEVA Fidelity has TEVA as undervalued now with strong sentiment for short term, mid term and long term. It has 93 score for its quality and 95 score for the financial strength. See you to $40 around the corner.

1 · Reply

incipit Jan. 13 at 4:58 PM

$TEVA Hi, I am new on board, convinced by the conference talk

0 · Reply

JawadAbuJaber Jan. 13 at 4:47 PM

$TEVA if we hit the 33.7 then really the sky is the limit, ton ton of money to be made, in a stock that doesnt guve a shit about gold/ bitcoin 📈

0 · Reply

SuperBusa Jan. 13 at 4:44 PM

$TEVA

0 · Reply

Turbofueled Jan. 13 at 2:22 PM

$LEXX $NVO $LLY $TEVA $MRK $LEXX coming to GLP-1 Market! “Our MTA partner is of great importance to us but is not our only business initiative. Lexaria has held a variety of discussions during 2025 – and expects this to intensify in 2026 – with a number of other pharmaceutical companies located in various jurisdictions around the world. DHT technology is not only being discussed within the GLP-1 drug sector, but also for other applications where Lexaria has completed previous investigatory work (e.g., for DHT-CBD for hypertension where we are ideally seeking to achieve strategic partner funding support for prospective future development activities of this Company asset), and even for brand-new drug sectors where DHT has never before been utilized. These discussions are being held with companies ranging in size from smaller regional companies up to and including some of the largest pharmaceutical companies in the world.”

0 · Reply

Jessypenny Jan. 13 at 10:17 AM

$DRTS $TEVA $DVAX $REGN Biotech Momentum. These 4 companies reached new 52-week highs yesterday and every day last week: Alpha Tau Medical (DRTS) - 7-day streak hitting $7.12 today. Teva Pharma (TEVA) - 6-day streak hitting $33.42 today. Dynavax (DVAX) - Daily highs since Jan 5, reaching $15.68 today. Phaarmasia Ltd - 10-day streak of new highs. Strength in clinical data and M&A speculation is driving the sector higher.

1 · Reply

Market Cap	37.44B
Revenue (ttm)	16.54B
Net Income (ttm)	-1.64B
EPS (ttm)	N/A
PE Ratio	12.59
Forward PE	12.35
Profit Margin	-9.91%
Debt to Equity Ratio	2.31

Volume	7,214,895
Avg Vol	11,581,242
Day's Range	N/A - N/A
Shares Out	1.15B
Stochastic %K	63%
Beta	0.66
Analysts	Strong Sell
Price Target	$33.55